INBX Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Chartmill - Mentions: SDA RNA CMBM ADTX ...

Unusual volume stocks in Thursday's session

5 days ago - By: Chartmill - Mentions: SOHO ITGR BYND BRTX ...

The trading volume of these stocks is deviating from the norm in today's session.

7 days ago - By: Benzinga - Mentions: F NUE WM KDP

US Stocks Jump To Records Amid Weak Inflation: Investor Fear Eases, Greed Index Remains In 'Fear' Zone

9 days ago - By: Chartmill - Mentions: MOFG GSIT YGMZ NEGG ...

Here are the top movers in Friday's session.

9 days ago - By: Benzinga - Mentions: NEM NSC BKR SSNC ...

Stocks Soar To Records After Weak Inflation, Ford Jumps 10%: What's Moving Markets Friday?

9 days ago - By: Chartmill - Mentions: FMFC MOFG YGMZ LAZR ...

What's going on in today's session

10 days ago - By: Chartmill - Mentions: DECK MOFG XFOR QLGN ...

Which stocks are gapping on Friday?

10 days ago - By: Chartmill - Mentions: DECK MOFG AMBI ASNS ...

Get insights into the top gainers and losers of Friday's pre-market session.

10 days ago - By: Stocktwits - Mentions: VTWO IWV

Why Is INBX Stock Rising Today?

10 days ago - By: Chartmill - Mentions: DECK CYH FIX ASX ...

Get insights into the top gainers and losers of Thursday's after-hours session.

10 days ago - By: Inhibrx Biosciences, Inc.

Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

11 days ago - By: Inhibrx Biosciences, Inc.

Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

3 months ago - By: The Motley Fool

Inhibrx Biosciences Beats Earnings

3 months ago - By: Inhibrx Biosciences, Inc.

Inhibrx Reports Second Quarter 2025 Financial Results

6 months ago - By: Inhibrx Biosciences, Inc.

Inhibrx Reports First Quarter 2025 Financial Results

7 months ago - By: Inhibrx Biosciences, Inc.

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

8 months ago - By: Inhibrx Biosciences, Inc.

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

10 months ago - By: Inhibrx Biosciences, Inc.

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer